Insider Buying: AnaptysBio, Inc. (NASDAQ:ANAB) Director Purchases $842,177.28 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc bought 65,184 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were purchased at an average cost of $12.92 per share, with a total value of $842,177.28. Following the completion of the acquisition, the director now owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. This represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock. The shares were purchased at an average price of $12.95 per share, for a total transaction of $86,065.70.

AnaptysBio Trading Up 9.3 %

Shares of NASDAQ ANAB opened at $14.60 on Friday. The stock has a market cap of $444.26 million, a PE ratio of -2.40 and a beta of -0.02. AnaptysBio, Inc. has a 12-month low of $12.51 and a 12-month high of $41.31. The company has a 50-day moving average of $19.75 and a 200 day moving average of $28.43.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. UBS Group raised their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and dropped their price target for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. Finally, Wedbush restated an “outperform” rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a research report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio in the third quarter valued at about $49,000. nVerses Capital LLC boosted its holdings in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares during the period. Finally, Point72 DIFC Ltd increased its holdings in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after buying an additional 5,342 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.